A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection

<p>Abstract</p> <p>Background</p> <p>Over the last several decades, as a result of an evolution in manufacturing processes, a marked development has been made in the field of gonadotropins for ovarian stimulation. Initially, therapeutic gonadotropins were produced from...

Full description

Saved in:
Bibliographic Details
Main Authors: Schneider Danielle T (Author), Verza Sidney (Author), Schertz Joan C (Author), Esteves Sandro C (Author), Zabaglia Silval FC (Author)
Format: Book
Published: BMC, 2009-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8dad2fa0657e411f9633c9b77fc97f3c
042 |a dc 
100 1 0 |a Schneider Danielle T  |e author 
700 1 0 |a Verza Sidney  |e author 
700 1 0 |a Schertz Joan C  |e author 
700 1 0 |a Esteves Sandro C  |e author 
700 1 0 |a Zabaglia Silval FC  |e author 
245 0 0 |a A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection 
260 |b BMC,   |c 2009-10-01T00:00:00Z. 
500 |a 10.1186/1477-7827-7-111 
500 |a 1477-7827 
520 |a <p>Abstract</p> <p>Background</p> <p>Over the last several decades, as a result of an evolution in manufacturing processes, a marked development has been made in the field of gonadotropins for ovarian stimulation. Initially, therapeutic gonadotropins were produced from a simple process of urine extraction and purification; now they are produced via a complex system involving recombinant technology, which yields gonadotropins with high levels of purity, quality, and consistency.</p> <p>Methods</p> <p>A retrospective analysis of 865 consecutive intracytoplasmic sperm injection (ICSI) cycles of controlled ovarian hyperstimulation (COH) compared the clinical efficacy of three gonadotropins (menotropin [hMG; n = 299], highly-purified hMG [HP-hMG; n = 330] and follitropin alfa [r-hFSH; n = 236]) for ovarian stimulation after pituitary down-regulation. The endpoints were live birth rates and total doses of gonadotropin per cycle and per pregnancy.</p> <p>Results</p> <p>Laboratory and clinical protocols remained unchanged over time, except for the type of gonadotropin used, which was introduced sequentially (hMG, then HP-hMG, and finally r-hFSH). Live birth rates were not significantly different for hMG (24.4%), HP-hMG (32.4%) and r-hFSH (30.1%; p = 0.09) groups. Total dose of gonadotropin per cycle was significantly higher in the hMG (2685 +/- 720 IU) and HP-hMG (2903 +/- 867 IU) groups compared with the r-hFSH-group (2268 +/- 747 IU; p < 0.001). Total dose of gonadotropin required to achieve clinical pregnancy was 15.7% and 11.0% higher for the hMG and HP-hMG groups, respectively, compared with the r-hFSH group, and for live births, the differences observed were 45.3% and 19.8%, respectively.</p> <p>Conclusion</p> <p>Although similar live birth rates were achieved, markedly lower doses of r-hFSH were required compared with hMG or HP-hMG.</p> 
546 |a EN 
690 |a Gynecology and obstetrics 
690 |a RG1-991 
690 |a Reproduction 
690 |a QH471-489 
655 7 |a article  |2 local 
786 0 |n Reproductive Biology and Endocrinology, Vol 7, Iss 1, p 111 (2009) 
787 0 |n http://www.rbej.com/content/7/1/111 
787 0 |n https://doaj.org/toc/1477-7827 
856 4 1 |u https://doaj.org/article/8dad2fa0657e411f9633c9b77fc97f3c  |z Connect to this object online.